May 15th 2024
Novo Holdings is expected to acquire 60% of Single Use Support, with the remaining shares being held by Danaher and the company founders.
Verona Pharma Receives $650M Investment from Oaktree Capital Management and OMERS Life Sciences
May 9th 2024Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.
Industry Business Check: Market Review Rates the Latest Full-Year Outputs
March 13th 2024A look at pharma and biotech financing, M&A, and stock market performance in 2023—and where developments may head next as company executives continue to navigate stormy but perhaps stabilizing waters in the months ahead.
Roche Ends Agreement With Repare Therapeutics to Develop ATR Inhibitor Camonsertib
February 13th 2024Roche halts agreement with Repare Therapeutics to develop and commercialize camonsertib just weeks after triggering a $40 million milestone payment when the first patient was dosed with the novel cancer drug.